| Literature DB >> 35451385 |
Xiuping Zhuo1, Meinv Huang, Meifang Wu.
Abstract
ABSTRACT: To observe whether obstructive sleep apnea syndrome (OSAS) can aggravate the cognitive dysfunction of patients with hypertension (HTN), and to explore other risk factors.One hundred one hypertensive patients were selected for information collection. After the polysomnography test, they were divided into HTN-obstructive sleep apnea (OSA) and HTN groups. The Montreal cognitive assessment and the mini-mental state examination scales were used to appraise the patients' cognitive function. Logistic regressive analysis was used to determine the risk factors of cognitive dysfunction in patients with HTN.Compared with the HTN patients, HTN-OSA patients performed worse in mini-mental state examination (25.5 ± 2.9 vs 23.5 ± 3.2; P = .01) and Montreal cognitive assessment (28 ± 1.58 vs 21.2 ± 3.96; P = .003), and patients in the HTN-OSA group seemed more likely to suffer from dementia (31% vs 66%; P < .01). The apnea-hypopnea index (AHI) in the HTN group was lower than HTN-OSA group. Through multivariate logistic regression analysis, we can found that alcohol drinking, body mass index, long-term medication, diabetes, hypercholesterolemia, coronary heart disease, and OSAS were the independent risk factors of cognitive dysfunction in patients with HTN.OSAS can aggravate the cognitive dysfunction of hypertensive patients, besides, drinking, high-body mass index, long-term medication, diabetes, hypercholesterolemia, and coronary heart disease were also the risk factors of cognitive dysfunction in patients with hypertension. The cognitive dysfunction of patients with HTN can benefit from sleep apnea treatment.Entities:
Mesh:
Year: 2022 PMID: 35451385 PMCID: PMC8913121 DOI: 10.1097/MD.0000000000028934
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Baseline characteristics.
| Characteristic | Total (n = 101) |
| Age in years, median (IQR) | 52 (22–86) |
| Gender (n, %) | |
| Male | 85 (84.2) |
| Female | 16 (15.8) |
| Cardiovascular risk factors (n, %) | |
| Diabetes mellitus | 11 (10.8) |
| Hypercholesterolemia | 43 (42.6) |
| Smoking | 57 (56.4) |
| Drink | 64 (63.4) |
| Long-term medication | 35 (34.6) |
| Coronary heart disease | 5 (4.9) |
| Education (yrs, median [IQR]) | 9 (0–16) |
| BMI, kg/m2 (n, %) | |
| BMI ≤ 18.5 | 1 (1) |
| 18.5 ≤ BMI ≤ 23.9 | 14 (13.9) |
| BMI ≥ 23.9 | 86 (85.1) |
| Type of cognitive disorder (n, %) | |
| Moderate cognitive impairment | 5 (4.8) |
| Mild cognitive impairment | 28 (27.7) |
| Clinical symptoms (n, %) | |
| Memory decline | 63 (62.3) |
| Decreased attention | 36 (35.6) |
| Lags in response | 35 (34.6) |
| Other types of symptoms | 26 (25.7) |
Comparision between HTN group and HTN-OSA group.
| Characteristic | HTN-OSA (n = 46) | HTN (n = 55) |
|
| Blood oxygen saturation (SpO2, %, median [IQR]) | 95 (71–98) | 97 (95–98) | .001 |
| % TRT SaO2 <90%, median (IQR) | 3.7 (0–87.7) | 1.2 (0–3.8) | .523 |
| SaO2 <90% time (min, median [IQR]) | 20.3 (0–576.5) | 15.6 (0–430) | .667 |
| Apnea-hypopnea index, median (IQR) | 16 (1–73) | 0.9 (0–2.7) | .001 |
| Polysomnogram parameters | |||
| Sleep efficiency | 77.9 ± 1.7 | 76.3 ± 1.7 | .568 |
| Wake up time after sleep, min | 150.6 ± 12.9 | 160.9 ± 11.9 | .59 |
| Total sleep time, min | 533.1 ± 12.2 | 519.2 ± 11.8 | .688 |
| Rapid eye movement sleep latency, min | 35.2 ± 3.6 | 44.1 ± 3.8 | .487 |
| Non rapid eye movement sleep time, min | |||
| N1 stage | 95.4 ± 11.2 | 95.2 ± 11.1 | .369 |
| N2 stage | 287.2 ± 10.1 | 269.2 ± 10 | .467 |
| N3 stage | 65.9 ± 6 | 77.2 ± 6.1 | .291 |
| SAS severity (n, %) | .137 | ||
| None ( | 12 (26.1) | 36 (65.5) | |
| Mild (5–15) | 20 (43.5) | 12 (21.7) | |
| Moderate (15–30) | 5 (10.9) | 3 (5.5) | |
| Severe ( | 9 (19.5) | 4 (7.3) | |
The MoCA and MMSE scores.
| Group name | HTN | HTN-OSA |
|
| MoCA (‘X ± S) | 21.2 ± 3.96 | 28 ± 1.58 | .003 |
| MMSE (‘X ± S) | 23.5 ± 3.2 | 25.5 ± 2.9 | .01 |
Analysis of related factors between patients with cognitive impairment and patients with normal cognition.
| Cognitive impairment group (n = 33) | Cognitive normal group (n = 68) | χ2/ |
| |
| Male (n, %) | 30 (90.9) | 55 (80.9) | 0.016 | .900 |
| Age in years (X ± S) | 61.19 ± 7.85 | 56.89 ± 8.07 | 0.031 | .861 |
| Diabetes mellitus | 6 (18.2) | 5 (7.4) | 8.032 | .004 |
| Hypercholesterolemia | 21 (63.6) | 22 (32.4) | 4.321 | .03 |
| Smoking | 18 (54.6) | 39 (57.4) | 1.230 | .823 |
| Drink | 27 (81.8) | 37 (54.4) | 7.113 | .000 |
| Long-term medication | 22 (66.7) | 13 (19.1) | 7.339 | .007 |
| Coronary heart disease | 3 (9.1) | 2 (2.9) | 6.466 | .000 |
| BMI, kg/m2 (n, %) | 5.939 | .000 | ||
| BMI ≤ 18.5 | 1 (3) | 0 | ||
| 18.5 ≤ BMI ≤ 23.9 | 5 (15.2) | 9 (13.2) | ||
| BMI ≥ 23.9 | 27 (81.8) | 59 (86.8) | ||
| OSAS | 26 (78.8) | 20 (29.4) | 8.063 | .005 |
Multivariate logistic analysis of cognitive dysfunction.
|
| SE |
| OR 95% CI | ||
| Diabetes mellitus | 0.119 | 0.330 | 1.130 | .033 | 2.888 (0.465–4.652) |
| Hypercholesterolemia | 0.321 | 0.334 | 0.921 | .037 | 1.378 (0.716–2.652) |
| Drink | 3.705 | 0.830 | 9.931 | <.001 | 4.032 (1.991–7.652) |
| Long-term medication | 1.698 | 0.541 | 9.836 | .002 | 5.46 (1.890–15.775) |
| Coronary heart disease | 0.317 | 0.235 | 1.820 | .017 | 2.728 (0.459–1.154) |
| BMI, kg/m2 | 0.140 | 0.356 | 3.235 | .026 | 1.958 (1.092–1.837) |
| OSAS | 1.235 | 0.789 | 5.326 | .001 | 2.562 (0.563–2.358) |